ArticleFrontiers in oncology2025
Case Report: Effective management of residual glioblastoma with combined modality therapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is an aggressive primary brain tumor with a poor prognosis, often characterized by rapid progression and resistance to conventional therapies. This case report discusses the comprehensive management of a 60-year-old female diagnosed with residual GBM following initial surgical intervention. The treatment regimen included craniectomy, concurrent chemoradiotherapy (CCRT), adjuvant temozolomide, and weekly sessions of modulated electro-hyperthermia (mEHT, Oncothermia). Remarkably, the patient exhibited significant tumor shrinkage, improved neurological symptoms, and an extended survival period compared to typical outcomes. mEHT was utilized to enhance the efficacy of chemoradiotherapy and temozolomide by selectively targeting cancer cells and improving drug delivery. Integrating mEHT into the standard treatment protocol appears to have contributed to better therapeutic outcomes and improved quality of life for the patient. This case underscores the potential benefits of incorporating mEHT into multimodal treatment strategies for GBM, highlighting its role in enhancing the effects of conventional therapies. Future research and clinical trials are warranted to further explore the synergistic effects of mEHT with standard GBM treatments, aiming to establish more effective protocols and improve overall patient survival and quality of life. This report adds to the growing body of evidence supporting the use of innovative, integrative approaches in the management of aggressive brain tumors like GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.